GSK share price surges after $2.2bn Zantac drug settlement
GSK’s shares rose by as much as 6.5% on Thursday before settling back slightly lower after it agreed a $2.2 billion settlement over lawsuits in the US, which alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer. The agreement was […]
GSK share price surges after $2.2bn Zantac drug settlement Read More »